Two developments point to AI’s expanding role in drug discovery: academic and industry groups released Boltz‑2, an AI model that predicts small‑molecule binding affinity at speed, and the Chan Zuckerberg Initiative expanded a partnership with NVIDIA to scale virtual cell models and data infrastructure. Boltz‑2 (MIT/Recursion) demonstrated rapid affinity estimates and benchmark performance, while the NVIDIA–CZI pact will scale compute for community virtual cell resources and models. Both advances target earlier, computationally driven hit triage and model‑driven translational research.